title: High rates of viral suppression after long-term entecavir treatment of Asian patients with hepatitis B e antigen-positive chronic hepatitis B.
abstract: There are limited data on the effects of long-term entecavir therapy in Asian patients with chronic hepatitis B (CHB). We performed a post hoc analysis of 94 Asian hepatitis B e antigen-positive (HBeAg+), nucleos(t)ide analogue-naive patients who received 5 years of therapy with entecavir (up to 2 years in study ETV-022 and the remainder in study ETV-901). Among patients completing week 240, 95% (63 of 66) had levels of hepatitis B virus DNA <300 copies/mL, and 76% (50 of 66) had normalized levels of alanine aminotransferase. In addition to patients who achieved a serologic response during ETV-022, a further 40% (26 of 65) achieved HBeAg loss, and 18% (12 of 65) underwent HBeAg seroconversion through year 5 of entecavir therapy. No resistance to entecavir was detected, and the safety profile was consistent with previous reports. The long-term efficacy and safety of entecavir are therefore comparable between Asians and the overall population of HBeAg+ patients with CHB.
authors.affiliation: Division of Liver Diseases, Mount Sinai School of Medicine, New York, New York 11355, USA. cpan11355@yahoo.com
authors.forename: Calvin Q
authors.initials: CQ
authors.lastname: Pan
authors.forename: Myron
authors.initials: M
authors.lastname: Tong
authors.forename: Kris V
authors.initials: KV
authors.lastname: Kowdley
authors.forename: Ke-Qin
authors.initials: KQ
authors.lastname: Hu
authors.forename: Ting-Tsung
authors.initials: TT
authors.lastname: Chang
authors.forename: Ching-Lung
authors.initials: CL
authors.lastname: Lai
authors.forename: Seung Kew
authors.initials: SK
authors.lastname: Yoon
authors.forename: Samuel S
authors.initials: SS
authors.lastname: Lee
authors.forename: David
authors.initials: D
authors.lastname: Cohen
authors.forename: Hong
authors.initials: H
authors.lastname: Tang
authors.forename: Naoky
authors.initials: N
authors.lastname: Tsai
mesh_terms: D000328:Adult; D000410:Alanine Transaminase / Q000097:blood; D000998:Antiviral Agents / Q000008:administration & dosage* / Q000009:adverse effects; D044466:Asian People; D004279:DNA, Viral / Q000097:blood; D024882:Drug Resistance, Viral; D064420:Drug-Related Side Effects and Adverse Reactions / Q000453:epidemiology; D005260:Female; D006147:Guanine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D006513:Hepatitis B e Antigens / Q000097:blood*; D006515:Hepatitis B virus / Q000302:isolation & purification*; D019694:Hepatitis B, Chronic / Q000188:drug therapy* / Q000821:virology; D006801:Humans; D008297:Male; D016896:Treatment Outcome; D019562:Viral Load
chemical_list: D000998:Antiviral Agents; D004279:DNA, Viral; D006513:Hepatitis B e Antigens; C413685:entecavir; D006147:Guanine; D000410:Alanine Transaminase